Treatment of adverse cardiovascular effects of cannabinoids

By using lignin or its derivatives as CB1 receptor antagonists, the adverse cardiovascular effects caused by cannabinoids were solved, effective prevention and treatment of cardiovascular diseases were achieved, and endothelial function and atherosclerosis were significantly improved. situation.

CN119095592AInactive Publication Date: 2024-12-06GREENSTONE BIOSCIENCES INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380029207.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-04-28
Filing Date
2023-04-26
Publication Date
2024-12-06
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

The use of cannabinoids leads to adverse cardiovascular effects, including myocardial infarction, angina, arrhythmias, endothelial dysfunction, atherosclerosis and metabolic dysfunction, and the prior art is difficult to effectively treat these problems.

Method used

Using lignin or its derivatives, the adverse cardiovascular effects caused by cannabinoids are inhibited by binding to cannabinoids, especially CB1 receptor antagonists, including treatment through oral administration, injection and other means.

Benefits of technology

Effectively prevent or reduce the adverse cardiovascular effects caused by cannabinoids, reverse or improve related clinical symptoms, reduce the risk of cardiovascular disease, and significantly improve endothelial function and atherosclerosis.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0005052599900000081
    Figure BDA0005052599900000081
  • Figure BDA0005052599900000111
    Figure BDA0005052599900000111
  • Figure BDA0005052599900000171
    Figure BDA0005052599900000171
Patent Text Reader

Abstract

The adverse cardiovascular effects of cannabinoids in a subject are treated with genistein or genistein derivatives.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the use of genistein or genistein derivatives to treat the adverse cardiovascular effects of cannabinoids. Background Art

[0002] Cannabinoids

[0003] Medical marijuana, or cannabis, has been used for thousands of years. Cannabis and its pharmaceutical preparations extracted from Cannabis indica and C. sativa have been used to treat nausea, inflammation, vomiting, and pain. The legalization of marijuana in many states has led to an increase in its recreational and medicinal use. The most important components of the cannabis plant are a group of phytochemicals called cannabinoids or phytocannabinoids, which give the cannabis plant its medical and recreational properties. Cannabinoids, whether as the cannabis plant or its parts, such as buds, or as resins or extracts (such as "hash oil"), are ingested in a variety of recreational ways, usually by smoking, "vaping" of extracts, or oral consumption of cannabis plants or parts or extracts in foods such as confections; and usually as a dosage form (e.g., capsules, sprays) containing known amounts of pure cannabinoids. The Institute of Medicine recommends testing alternative cannabinoid delivery systems to smoking and conducting clinical trials to evaluate the efficacy of synthetic and plant-derived cannabinoids for the treatment of spasticity, movement disorders, glaucoma, and other indications. As described below, cannabinoid preparations containing natural or synthetic cannabinoids are available as prescription drugs in some countries.

[0004] Cannabinoids are a diverse class of compounds that act on cannabinoid receptors in cells, altering the release of neurotransmitters in the brain. More than 100 cannabinoids have been identified in cannabis, the four most important of which are Δ 9 -Tetrahydrocannabinol (Δ 9 -THC, THC, (6aR, 10aR) -6,6,9-trimethyl-3-pentyl-6a,7,8,10a-tetrahydro-6H-benzo[c]pyran-1-ol), cannabidiol (CBD, 2[(1R, 6R) -6-isopropenyl-3-methyl-2-cyclohexen-1-yl] -5-pentyl-1,3-benzenediol), Δ 8 -Tetrahydrocannabinol (Δ 8-THC, (6aR)-6,6,9-trimethyl-3-pentyl-6a,7,10,10a-tetrahydro-6H-benzo[c]pyran-1-ol); and cannabinol (CBN, 6,6,9-trimethyl-3-pentyl-6H-benzo[c]pyran-1-ol); wherein Δ 9 -THC and CBD have been the most extensively studied. 9 -THC and Δ 8 -THC has psychoactive properties, while CBD is reported to have anxiolytic, antipsychotic, antiemetic, and anti-inflammatory properties, but does not exhibit the psychoactive properties of THC. 9 -THC and CBD are biosynthesized from the common precursor olivetol to Δ 9 -Tetrahydrocannabinolic acid and cannabidiolic acid.

[0005] Both THC and CBD exert their effects by interacting with the G protein-coupled receptors (GPCRs) cannabinoid receptor 1 (CB1) and cannabinoid receptor 2 (CB2) with varying affinities. While CB1 receptors are abundantly expressed in the brain and central nervous system regions, and at lower levels in peripheral tissues; the less studied CB2 receptors have been identified as being localized to immune cells, tonsils, and spleen. CB1 receptors have been identified as playing an important role in pain perception, memory, motor regulation, appetite, mood, and sleep, and mediate the psychoactive effects of THC and related cannabinoids; whereas CB2 receptors have been associated with anti-inflammatory, pain relief, and reduced tissue damage. Physiologically, when activated by short-lived endocannabinoids such as anandamide and 2-arachidonoylglycerol, CB1 and CB2 trigger a downstream cascade of events that mediate homeostasis and healthy function. In contrast, the cannabinoids THC and CBD interact directly or indirectly with CB1 and CB2 with varying affinities, modulating the activity of these receptors over a longer period of time.

[0006] It is well known that cannabinoids, especially CBD and THC, have many medicinal benefits. Conditions include post-traumatic stress disorder, neuropathic and chronic pain, pulmonary hypertension, systemic hypertension, insomnia, nausea, inflammation, arthritis, migraines, cancer, Crohn's disease, fibromyalgia, Alzheimer's disease, multiple sclerosis, glaucoma, attention deficit hyperactivity disorder (ADHD), sleep apnea, and decreased appetite. CBD's subtle effects are mainly manifested in pain, inflammation, and anxiety relief, among other medicinal values. CBD also does not have any of the adverse side effects that may occur when ingesting THC. Unlike THC, CBD also does not cause a high. CBD also seems to counteract the sleep-inducing effects of THC, which may explain why some cannabis strains are known to increase alertness.

[0007] The U.S. Food and Drug Administration (FDA) has approved two synthetic cannabinoids for the treatment of chemotherapy-induced nausea and vomiting and HIV-related anorexia: dronabinol, a synthetic Δ 9 -THC, as MARINOL capsules; and nabilone, 1-hydroxy-6,6-dimethyl-3-(2-methyl-2-octyl)-6,6a,7,8,10,10a-hexahydro-9H-benzo[c]pyran-9-one, a THC analog, as CESAMET capsules. Synthetic cannabinoids have also been associated with adverse cardiovascular effects. CBD is also approved as EPIDIOLEX oral solution for the treatment of seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex in patients 1 year of age and older. Nabiximols is a cannabis extract whose main active ingredients are THC and CBD. It is approved in multiple countries (although not in the United States) as SATIVEX oral spray for the treatment of neuropathic pain, spasticity, overactive bladder, and other symptoms of multiple sclerosis, with each spray containing 2.7 mg THC and 2.5 mg CBD.

[0008] DeFillipis et al., “Cocaine and marijuana use among young adults with myocardial infarction”, J. Am. Coll. Cardiol., 71, 2540-2551 (2018) showed in a cohort of 2097 patients that marijuana was associated with MI in young adults, controlling for other demographic factors. Previous studies have shown that CB1 activation is pro-atherogenic by promoting inflammation and oxidative stress, while CB2 activation is anti-atherogenic. Retrospective studies have shown that marijuana use increases the risk of cardiovascular disease (CVD), including myocardial infarction (MI), angina, and arrhythmias. Marijuana exposure induces endothelial dysfunction, atherosclerosis, cardiomyopathy, and metabolic dysfunction in animal models. Therefore, “adverse cardiovascular effects of cannabinoids” include the various effects mentioned in this paragraph.

[0009] CB1 antagonists have been shown to have anti-atherosclerotic effects, while CB2 agonists are being developed for vascular disease. CBD has a low affinity for cannabinoid CB1 and CB2 receptors, but despite this low affinity, it can act as an antagonist of CB1 / CB2 agonists. CBD can act as an inverse agonist of GPR3, GPR6, and GPR12. CBD has been shown to act as a serotonin 5-HT receptor. 1AIt is a partial agonist of the opioid receptor, and this action may be involved in its antidepressant, anxiolytic and neuroprotective effects. It is also an allosteric modulator of μ- and δ-opioid receptors. The pharmacological effects of CBD may involve PPARγ agonism and intracellular calcium release.

[0010] Because recreational and medicinal cannabinoid users, such as recreational marijuana smokers and pharmaceutical users of cannabinoid-containing medications such as dronabinol and nabilone, are at risk for adverse cardiovascular effects of these cannabinoids, it is desirable to find treatments for these adverse cardiovascular effects.

[0011] Genistein

[0012] Genistein, 5,7-dihydroxy-3-(4-hydroxyphenyl)-4H-1-benzopyran-4-one; 4′,5,7-trihydroxyisoflavone; sometimes mistakenly written as 4′,5,7-trihydroxyflavone, is a phytoestrogen belonging to the class of soybean isoflavones. It was first isolated from dyewood (dyer's broom) Genista tinctoria in 1899; its structure was established in 1926; and in 1928, it was chemically synthesized (Walter, "Genistin (an Isoflavone Glucoside) and its Aglucone, Genistein, from Soybeans", J. Am. Chem. Soc., 63 (12), 3273-3276 (1941)). Among soybean isoflavones, genistein ranks first in the number of experimental and clinical studies. Genistein itself is present in low levels in soybeans, but is present in high levels in fermented soybean-derived foods such as miso and natto. It is also widely distributed in leguminous plant foods and seeds, fruits and vegetables such as alfalfa and alfalfa sprouts, broccoli, cauliflower, sunflower, barley flour, caraway seeds and alfalfa seeds. It is widely used in the United States as a nutritional supplement, often in combination with other isoflavones such as genistin (genistein 7-O-β-D-glucoside) and daidzein.

[0013] Many genistein derivatives have been synthesized: Spagnuolo et al., "Genistein and Cancer: Current Status, Challenges, and Future Directions", Adv. Nutr., 6, 408-419 (2015) stated: "On this basis and due to the known beneficial biological effects of genistein, chemists have been encouraged to synthesize many derivatives of this compound and improve the pharmacological properties. For example, FA esterification, 6-carboxymethyl, nitrooxy, 7-O heterocycle, 7-O-β-D glucoside and 7-O-β-D-glucuronic acid, halogenation, deoxybenzoin, benzylation, hydroxylation, esterification, benzenesulfonate, dimethylaminomethyl, phenoxyalkylcarboxylic acid, sugar conjugate and alkylbenzylamine derivatives of genistein have been reported to date", which cited 15 references. As several examples of literature on genistein derivatives, Grynkiewicz et al., "X-ray and 13C CP MAS investigations of structure of two genisteinderivatives", J. Mol. Struct., 694, 121-129 (2004), reported the synthesis of 7-O-(tert-butyldimethylsilyl) ether and 7-O-(tetrabutylammonium) salt of genistein, which can be used as intermediates for other 7 substituted genistein derivatives. Rusin et al., "Synthetic conjugates of genistein affecting proliferation and mitosis of cancer cells", Bioorg. Med. Chem., 19, 295-305 (2011), reported the synthesis of 7-O-ω-hydroxyalkyl genistein and its conjugates. Szeja et al., "Selective alkylation of genistein and daidzein", Chem. Biol. Interface, 3, 95-106 (2013), describe the regioselective 7-O- and 4-O-alkylation of genistein, including the preparation of dialkylated derivatives; whereas Byczek et al., "Genistein Derivatives Regioisomerically Substituted at 7-O- and 4′-O-Have Different Effect on the Cell Cycle", J. Chem., 2013, 191563 describe further regioisomerically substituted genistein derivatives.Castro et al., "Synthesis of Lipophilic Genistein Derivatives and Their Regulation of IL-12 and TNF-α in Activated J774A.1 Cells", Chem. Biol. Drug Des., 79, 347-352 (2012) reported the synthesis of acylated and alkylated derivatives of genistein, including a general scheme for the synthesis of such genistein derivatives.

[0014] Crystalline genistein monohydrate and crystalline genistein salts such as sodium, potassium, calcium, magnesium, L-lysine and N-methylglucamine salts are known in, for example, PCT International Publication No. WO 2010 / 068861 A1 “Crystalline forms of genistein”, Axcentua Pharmaceuticals AB.

[0015] Genistein affects multiple biochemical functions of living cells: it is a full agonist of estrogen receptor β (ERβ; EC 50 =7.6 nM), and to a lesser extent about 20-fold, is a full or partial agonist of ERα; is an agonist of the G protein-coupled estrogen receptor (affinity = 133 nM); and is an activator of the peroxisome proliferator-activated receptor; and is an inhibitor of several tyrosine kinases, EFGR kinase, and BCR-ABL protein-specific tyrosine kinase. Genistein is reported to be an agonist of human CB1, IC 50 =0.15 μM, Ki =0.14 μM, and is an agonist of human CB2, IC 50 and Ki are >50 μM. Genistein is a well-studied anticancer agent reported to be active through multiple mechanisms, including as an angiogenesis inhibitor, DNA topoisomerase II inhibitor, and tyrosine kinase inhibitor. Reports on the effects of genistein on appetite are mixed.

[0016] Although genistein is widely used as a dietary supplement in the United States, it is well known that despite its high cell wall permeability, genistein has low solubility and therefore low bioavailability; and various attempts have been made to improve the bioavailability of genistein by chemical modification (see the first paragraph of this section) and by physical means, such as by grinding into submicron particles and administering as a suspension (see PCT International Publication Nos. WO 2012 / 068140 A1, "Nanoparticle isoflavone compositions & methods of making and using the same", and WO 2015 / 081018A1, "Suspension compositions of physiologically active phenolic compounds & methods of making and using the same", both belonging to Humanetics Corporation). Humanetics' suspension formulation BIO 300 contains 325 mg / mL of wet-ground genistein with an average particle size of 200 nm and has been tested in animal and human Phase 1 clinical studies.

[0017] It is well known that genistein can protect against radiation-induced fibrosis in animal models, and several articles describe the protective effect of Humanetics BIO 300 formulations in radiation-induced fibrosis mouse models. See, for example, Jackson et al., "BIO 300, a nanosuspension of genistein, mitigates pneumonitis / fibrosis following high-dose radiation exposure in the C57L / J murine model", Br. J. Pharmacol., 174 (24), 4738-4750 (2017) and Singh et al., "A novel formulation of BIO 300 confers prophylactic radioprotection from acute radiation syndrome in mice", Int. J. Radiat. Biol., 98 (5), 958-967 (2022). The latter article introduces the preparation details of BIO 300 injection, oral suspension and powder formulation in the "Test and Control Items" section. Summary of the invention

[0018] The present invention is genistein or genistein derivatives for use in treating the adverse cardiovascular effects of cannabinoids.

[0019] In another aspect, the present invention includes a pharmaceutical composition comprising a cannabinoid and genistein or a genistein derivative.

[0020] Since genistein has been shown to treat Δ 9 -Adverse cardiovascular effects of THC, genistein and genistein derivatives hold promise for treating the adverse cardiovascular effects of cannabinoids in humans.

[0021] Preferred embodiments of the present invention are characterized by the technical features of the description of the present application as filed and claims 1 to 15 . DETAILED DESCRIPTION

[0022] definition

[0023] The section entitled "Cannabinoids" in the Background of the Invention describes "cannabinoids"; including THC, nabilone and CBD; particularly those cannabinoids that act as CB1 agonists, such as THC. Unless the context requires otherwise, the term "cannabinoid" includes more than one cannabinoid ("cannabinoids") and, for example, includes the cannabis plant and parts thereof, such as buds, cannabis resin, cannabis extracts, such as "cannabis oil", etc., as well as cannabis or cannabis extract-containing foods (as long as they contain one or more cannabinoids), and prescription drugs containing cannabinoids.

[0024] The sixth paragraph of the subsection entitled "Cannabinoids" in the section entitled "Cannabinoids" in the Background Art describes "Adverse cardiovascular effects of cannabinoids". Specifically, these adverse cardiovascular effects are adverse cardiovascular effects associated with the CB1 agonist effects of cannabinoids. In specific aspects, the adverse cardiovascular effects are one or more effects selected from the group consisting of myocardial infarction (MI), angina pectoris, arrhythmia, endothelial dysfunction, atherosclerosis, cardiomyopathy and metabolic dysfunction.

[0025] "Genistein" is described in the section entitled "Genistein" in the Background Art.

[0026] "Genistein or a genistein derivative" refers to a compound of formula I:

[0027]

[0028] or a pharmaceutically acceptable salt thereof,

[0029] Where R 1 , R 2 and R 3Each independently selected from H, (HO)2P(O)-, HOS(O)2-, H2NS(O)2-, H(OCH2CH2) 1-10 -, (CH3)2NCH2CH2-, morpholinyl, (C 1-6 alkyl)C(O)-[wherein C 1-6 The alkyl group may be optionally substituted by 1 or 2 groups selected from halogen, hydroxyl, C 1-4 Alkoxy, amino, C 1-4 The term "genistein derivative" refers to a compound of formula I as defined above, wherein R 1 , R 2 and R 3 At least one is not H. "Genistein or a genistein derivative" includes crystalline and amorphous forms as well as micronized forms of these compounds, including in formulations such as Humanetics Corporation BIO 300 suspension. Unless the context requires otherwise, the term "genistein" means "genistein or a genistein derivative" as defined in this paragraph.

[0030] The salt (for example, pharmaceutical salt) of genistein or genistein derivative is included in the present invention, and is applicable to the method described in the present application.These salts are preferably formed with pharmaceutical acid or base as appropriate.For example, for extensive discussion of pharmaceutical salts and their selection, preparation and usage, refer to "Handbook of Pharmaceutically Acceptable Salts", Stahl and Wermuth, eds., Verlag Helvetica Chimica Acta, Zürich, Switzerland. Unless the context requires otherwise, any reference to genistein or genistein derivative is a reference to the compound and its salt.Genistein can exist as a non-salt compound, but it is known that it is a salt with an alkali metal and a nitrogenous base (for example, tromethamine), for example, the aforementioned PCT Publication No. WO 2010 / 068861 discloses an alkali metal and a nitrogenous base salt.

[0031] A "therapeutically effective amount" of genistein or a genistein derivative means that when the genistein derivative is administered to a human for treating the adverse cardiovascular effects of cannabinoids, the amount of each genistein or its derivative is sufficient to exert a therapeutic effect on the adverse cardiovascular effects of cannabinoids.

[0032] “Treating” or “treatment” of adverse cardiovascular effects of cannabinoids in humans includes one or more of the following:

[0033] (1) Preventing or reducing the risk of adverse cardiovascular effects of cannabinoids, i.e., preventing subjects who may be susceptible to adverse cardiovascular effects but have not yet developed or shown symptoms from developing clinical symptoms of adverse cardiovascular effects (i.e., prevention);

[0034] (2) inhibiting the adverse cardiovascular effects of cannabinoids, i.e., preventing or reducing the development of adverse cardiovascular effects or their clinical symptoms; and

[0035] (3) Alleviate the adverse cardiovascular effects of cannabinoids, that is, eliminate, reverse or improve the adverse cardiovascular effects, or reduce the number, frequency, duration or severity of their clinical symptoms.

[0036] Although "treatment" may include "cure", "treatment" does not necessarily mean "cure" or complete treatment, for example, treating all clinical symptoms of adverse cardiovascular effects of cannabinoids. Instead, "treatment" means that taking genistein derivatives can provide clinical benefits compared to not taking genistein or genistein derivatives; and treatment can also be evaluated by the improvement of biomarkers of adverse cardiovascular effects of the cannabinoid being treated.

[0037] The therapeutically effective amount for a particular subject will vary depending on the health and physical condition of the subject to be treated, the degree of adverse cardiovascular effects of the cannabinoids, the medical condition assessment and other relevant factors. It is expected that the therapeutically effective amount will fall within a relatively wide range that can be determined by routine experimentation.

[0038] "Comprising" or "containing" and grammatical variations thereof are inclusive rather than limiting words, and are meant to specify the presence of stated components, groups, steps, etc., but not to exclude the presence or addition of other components, groups, steps, etc. Thus, "comprising" does not mean "consisting of," "consisting essentially of," or "consisting only of," and, for example, a formulation "comprising" a compound must contain the compound, but may also contain other active ingredients and / or excipients.

[0039] Subjects suitable for treatment with the present invention

[0040] Suitable subjects for treatment according to the present invention are humans suffering from adverse cardiovascular effects of cannabinoids.

[0041] Genistein derivatives and their synthesis

[0042] Genistein derivatives of particular interest are those that are monosubstituted at the 4′ or 7 position or disubstituted at the 4′ and 7 positions, i.e., R 2 is hydrogen and R 1 and / or R3 Those compounds where R is not hydrogen; although trisubstituted compounds are also of interest. 1 , R 2 and R 3 When any one or more of is an "acyl group of an amino acid", the amino acid is specifically alanine, aspartic acid, cysteine, glutamic acid, glycine, valine, isoleucine, leucine, methionine, phenylalanine, proline, serine, threonine, tyrosine or tryptophan. 1 , R 2 and R 3 When any one or more are "acyl groups of hydroxy acids", the hydroxy acids are specifically ω-hydroxy acids such as δ-hydroxyvaleric acid and the like.

[0043] Genistein derivatives of particular interest are compounds of formulae Ia to Il:

[0044]

[0045] and pharmaceutically acceptable salts thereof.

[0046] The genistein derivatives of the present invention can be prepared by conventional organic synthesis methods well known to ordinary technicians in the field, taking into account the knowledge and known methods for the synthesis of genistein derivatives exemplified in the second and third paragraphs of the subsection entitled "Genistein" in the background technology.

[0047] For example, as described in the literature Szeja et al, 4'-O-alkylation can be carried out by treating genistein with an excess of a strong base such as potassium tert-butoxide in an aprotic solvent such as dimethylformamide (DMF), followed by the addition of a relevant alkylating agent such as an alkyl halide or sulfonate. 7-O-alkylation can be conveniently carried out by preparing a tetrabutylammonium salt of genistein, as described in the literature Grynkiewicz et al, reacting a methanol suspension of genistein with a slightly excess of aqueous tetrabutylammonium hydroxide, followed by treating the salt with a relevant alkylating agent in an aprotic solvent. Dialkylation can be conveniently carried out by 4'-O-alkylation of a 7-O-alkylated genistein derivative.

[0048] The acylation reaction of genistein or genistein alkylated derivatives can be conveniently carried out by conventional methods, such as the reaction of genistein with relevant acid in coupling agents such as dicyclohexylcarbodiimide and hydroxybenzotriazole in aprotic solvents such as dichloromethane. By treating the reaction mixture with hydrochloric acid, acylated genistein can be conveniently separated into salts, for example, hydrochloride. Other methods include using acyl halides or acid anhydrides and organic bases such as triethylamine, pyridine or dimethylaminopyridine in aprotic solvents such as dichloromethane again. Genistein phosphonate derivatives can be carried out according to standard procedures using genistein and phosphonyl halides (such as phosphonyl chloride) under similar conditions; the same is true for genistein sulfonates and sulfonamides using relevant sulfonyl halides.

[0049] In each case, the identity of the product can be confirmed using conventional analytical methods such as nuclear magnetic resonance.

[0050] Preparation and administration

[0051] Genistein or genistein derivatives can be administered by any route suitable for the subject to be treated and the nature of the subject's condition. Administration routes include oral administration (if feasible, usually preferred); injection administration, including intravenous, intraperitoneal, intramuscular and subcutaneous injection; administration by transmucosal (such as intranasal, oral, sublingual, rectal or vaginal) or transdermal (topical) delivery; and the like. The preparation can be an oral preparation (for example, a tablet, capsule or oral solution or suspension); an injection preparation (such as a solution); and a preparation designed for administration through a mucosa or transdermal administration. Suitable preparations for each of these administration methods can be consulted, for example, "Remington: The Science and Practice of Pharmacy", 20th ed., Gennaro, ed., Lippincott Williams & Wilkins, Philadelphia, Pa., USA. Because genistein and statins are usually oral, typical preparations are oral, and typical dosage forms will be tablets or capsules for oral administration. Intravenous formulations may be particularly suitable for administration to acutely ill subjects, such as those who may be hospitalized.

[0052] Depending on the intended mode of administration, the pharmaceutical composition may be in solid, semisolid or liquid dosage form, preferably in a unit dosage form suitable for single precise administration. In addition to an effective amount of a tyrosine kinase inhibitor and / or a statin, the composition may also contain suitable pharmaceutical excipients, including adjuvants that aid in processing the active compound into a pharmaceutically acceptable formulation. "Pharmaceutically acceptable excipient" refers to an excipient or mixture of excipients that does not interfere with the effectiveness of the biological activity of the active compound and is non-toxic or otherwise undesirable to the subject to which it is administered.

[0053] For solid compositions, conventional pharmaceutical excipients include, for example, pharmaceutical grade mannitol, lactose, starch, magnesium stearate, sodium saccharin, talc, cellulose, glucose, sucrose, magnesium carbonate, etc. Liquid pharmacology can be administered by dissolving, dispersing, etc., the active compound described herein and optional pharmaceutical adjuvants in water or aqueous excipients (such as water, saline, glucose aqueous solution, etc.) to form a solution or suspension. If necessary, the pharmaceutical composition to be administered may also contain a small amount of non-toxic auxiliary excipients such as wetting agents or emulsifiers, pH buffers, etc., for example, sodium acetate, sorbitan monolaurate, triethanolamine sodium acetate, triethanolamine oleate, etc. When a liquid suspension is used, the active agent can be combined with an emulsifying and suspending excipient. If necessary, flavoring agents, colorants and / or sweeteners may also be added. Other optional excipients for incorporation into oral preparations include preservatives, suspending agents, thickeners, etc.

[0054] Nanoparticle preparations of genistein or genistein derivatives, such as genistein submicron particle suspensions developed by Humanetics Corporation and described in PCT International Publication Nos. WO 2012 / 068140A1, “Nanoparticle isoflavone compositions & methods of making and using the same” and WO 2015 / 081018A1, “Suspension compositions of physiologically active phenolic compounds & methods of making and using the same” by Humanetics Corporation, may be of particular interest.

[0055] In one embodiment, using, for example, dynamic light scattering (DLS) detector measurement, the nanoparticles of genistein or genistein derivatives in the preparation can have a particle diameter less than 250nm (0.25 micron), and can have a median (average) particle diameter less than about 200nm, less than 150nm, less than 100nm, less than about 90nm, less than about 80nm, less than about 70nm or less than about 60nm. In a further example, the particle can have a median particle diameter less than about 50nm, less than about 40nm or less than about 30nm. In another embodiment, the average particle diameter is about 7nm-about 90nm. In another embodiment, the average particle diameter is about 5nm-70nm, 10nm-50nm, 10nm-30nm or 7nm-10nm. In a specific example, the particle can have a median particle diameter of about 30nm-about 10nm (for example, about 25nm).

[0056] In another embodiment, the nanoparticle preparation of genistein or a genistein derivative (i.e., nanoparticle preparation) can be a suspension preparation, which includes nanoparticles of genistein or a genistein derivative suspended in a suspension medium consisting of one or more carriers, excipients and / or diluents. Pharmaceutical carriers, excipients and diluents suitable for therapeutic use are well known in the pharmaceutical field, and, for example, are described in Remington's pharmaceutical Sciences, Mack Publishing Co. (AR Gennaro (Ed.) (1985)). In another embodiment, the nanoparticle preparation of genistein or a genistein derivative can be a suspension, which includes nanoparticles suspended in a suspension medium including a water-soluble polymer and a nonionic surfactant. The pharmaceutical composition can be formulated to be suitable for oral and parenteral administration. As disclosed herein, according to the specific preparation adopted, the "suspension" of nanoparticles can also include a measurable amount of genistein or a genistein derivative dissolved in a suspension medium.

[0057] The above-mentioned nanoparticle preparation can be prepared using a known method for preparing nanoscale particles. For example, genistein or genistein derivatives can be nano-grinded according to grinding techniques known in the art, including wet bead grinding and fine wet grinding of continuous dispersion using agitator bead mill in a horizontal grinding container. Alternatively, grinding can use a bead mill such as DYNO-mill (CB Mills, Gurnee, Ill.) to provide a dispersion. See, for example, Loh et al., "Overview of milling techniques for improving the solubility of poorly water-soluble drugs", Asian J. Pharm. Sci., 10, 255-274 (2015).

[0058] In one embodiment, the nanoparticle preparation can be prepared by adding genistein or genistein derivatives suspended in a pharmaceutical suspension medium to a bead mill and grinding in a manner that produces a pharmaceutical preparation characterized by the nanoparticle preparation in the pharmaceutical suspension medium. The preparation can be nano-grinded by recirculating the volume of the suspension through the bead mill, and then one or more times through the bead mill to prepare a pharmaceutical composition with a desired particle size distribution. The particle size of the suspended nanoparticles in the pharmaceutical composition can be controlled by adjusting the parameters and grinding conditions of the bead mill, including bead size, bead loading / suspension weight ratio, suspension composition, stirring rate and grinding time.

[0059] Alternatively, nanoparticle preparations can be prepared by using one or more known wet milling techniques, supercritical or compressed fluid techniques, heat or high pressure homogenization, emulsification techniques, evaporative precipitation, antisolvent precipitation, microprecipitation, cryogenic techniques, complexation techniques, ultrasonic techniques, or solid dispersion techniques known in the art. Spray drying and freeze drying can be used for post-processing to isolate nanoparticles that can be prepared by aqueous or solvent dispersion techniques.

[0060] In one embodiment, the nanoparticle formulation may comprise nanoparticle genistein or a genistein derivative having a D(0.50) of less than 1.0 μm, less than 0.8 μm, less than 0.7 μm, less than 0.5 μm, or less than 0.3 μm.

[0061] The nanoparticle formulation may include one or more surfactants or solubilizers, which may be selected from Poloxamer 188, polysorbate 80, polysorbate 20, Vit E-TPGS (TPGS), TPGS-750-M, TPGS-1000, Solutol HS15, PEG-40 hydrogenated castor oil (Cremophor RH40, Cremopher RH60), PEG-35 castor oil (Cremophor EL), PEG-8-glyceryl caprylate / caprylate (Labrasol), PEG-32-glyceryl laurate (Gelucire 44 / 14), PEG-32-glyceryl palmitostearate; polysorbate 85, polyglyceryl-6-dioleate (Caprol MPGO), a mixture of high and low HLB emulsifiers; sorbitan monooleate (Span 80), Capmul MCM, Maisine 35-1, monoolein, monolinolein, PEG-6-glyceryl oleate (Labrafil M 1944CS), PEG-6-glyceryl linoleate (Labrafil M2125CS), oleic acid, linoleic acid, propylene glycol monocaprylate (e.g., Capmul PG-8 or Capryol 90), propylene glycol monolaurate (e.g., Capmul PG-12 or Capryol 90), polypropylene glycol monolaurate (Plurol Oleique CC497), wherein the solubilizer is present in the formulation in an amount of about 0.01 wt%-10 wt%, or about 0.2%-1% (w / w).

[0062] Nanoparticle formulations can include one or more water-soluble polymers. Suitable water-soluble polymers include plant gums such as alginates, pectins, guar gum and xanthan gum, modified starches, polyvinylpyrrolidone (PVP), hydroxypropylmethylcellulose (HPMC), povidone K17, methylcellulose, and other cellulose derivatives such as sodium carboxymethylcellulose and hydroxypropylcellulose.

[0063] Typically, pharmaceutical compositions of genistein and genistein derivatives are packaged in containers with a label or instructions, or both, indicating that the pharmaceutical composition is used to treat an adverse cardiovascular effect of a cannabinoid.

[0064] The suitable amount of genistein derivatives for oral administration (subjects with adverse cardiovascular effects of cannabinoids may also receive other therapies in addition to the genistein or genistein derivatives discussed in this application) is expected to be 1-5 mg / Kg / day. That is, the suitable amount of genistein or genistein derivatives for oral administration is expected to be similar to the amount used for the treatment of prostate cancer in current clinical practice when used alone.

[0065] A person of ordinary skill in the art of treating the adverse cardiovascular effects of cannabinoids will be able to determine a therapeutically effective amount of genistein or a genistein derivative based on the specific subject and the nature and extent of the adverse cardiovascular effect, thereby obtaining a therapeutically effective amount without undue experimentation, relying on personal knowledge and the disclosure of this application.

[0066] synthesis

[0067] Synthesis 1. Synthesis of [4-[5,7-bis(2-methylpropionyloxy)-4-oxy-pyran-3-yl]phenyl]2-methylpropanoate (Ib)

[0068]

[0069] A round-bottom flask was charged with 5,7-dihydroxy-3-(4-hydroxyphenyl)pyran-4-one (500 mg, 1.85 mmol), 2-methylpropanoyl 2-methylpropanoate (878 mg, 5.55 mmol) and DMAP (677 mg, 5.5 mmol) in DCM (10 mL). The reaction mixture was stirred overnight at room temperature. After completion, the reaction mixture was concentrated under reduced pressure. Chromatography (SiO2; 0-100% DCM / hexane) provided the title product as a white solid (0.18 g; 20%).

[0070] 1 H NMR (500 MHz, CDCl3) δ 7.88 (d, J = 1.7 Hz, 1H), 7.53-7.45 (m, 2H), 7.22 (t, J = 2.0 Hz, 1H), 7.12 (dd, J = 8.6, 1.8 Hz, 2H), 6.83 (t, J = 2.0 Hz, 1H), 3.05-2.94 (m, 1H), 2.82 (ddtd, J = 14.0, 8.9, 7.0, 1.7 Hz, 2H), 1.39-1.30 (m, 18H).

[0071] Synthesis 2. Synthesis of [4-[5-hydroxy-7-(2-methylpropionyloxy)-4-oxy-pyran-3-yl]phenyl] 2-methylpropanoate (Ie)

[0072]

[0073] A round-bottom flask was charged with 5,7-dihydroxy-3-(4-hydroxyphenyl)pyran-4-one (500 mg, 1.85 mmol), 2-methylpropanoyl 2-methylpropanoate (585 mg, 3.7 mmol) and DMAP (248 mg, 2.03 mmol) in DCM (10 mL). Pyridine (0.44 mL, 5.55 mmol) was added and the reaction mixture was stirred at room temperature overnight. After completion, the reaction mixture was concentrated under reduced pressure. Chromatography (SiO2; 0-25% EtOAc in hexane) provided the title product as a white solid (0.11 g; 14%).

[0074] 1 H NMR (500MHz, CDCl3) δ12.74 (s, 1H), 7.97 (s, 1H), 7.57-7.53 (m, 2H), 7.19-7.16 (m, 2H), 6.76 (d, J=2.1Hz, 1H), 6.58 (d, J=2.1Hz, 1H), 2.85-2.80 (m, 2H), 1.34 (d, J=7.0Hz, 12H).

[0075] Synthesis 3. Synthesis of [4-[5,7-dihydroxy-4-oxy-pyran-3-yl]phenyl]5-hydroxyvalerate (I1)

[0076]

[0077] In dimethylformamide, in the presence of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride and 4-dimethylaminopyridine, genistein was acylated with 5-(tert-butyldimethylsilyloxy)pentanoic acid to give a mixture consisting mainly of 4′-esters. After purification, the hydroxyl protecting group on the pentanoate was removed by hydrolysis with tetrabutylammonium fluoride and acetic acid in tetrahydrofuran to give Il with a purity of 95%.

[0078] The tris(3-methylbutyrate) derivative Ic is prepared in the same manner as Ib, but using 3-methylbutyryl-3-methylbutyrate; the di(3-methylbutyrate) derivative Id and the di(acetate) derivative If are prepared in the same manner as Ie, but using 3-methylbutyryl-3-methylbutyrate and acetic anhydride, respectively. Mixed derivatives such as Ig and Ih are prepared by monoacylation at the 4′-position of genistein with a single equivalent of a suitable anhydride (e.g., acetic anhydride of Ig), and then further acylation at the 7-position using a single equivalent of a suitable anhydride or acyl halide such as 2-acetoxyacetyl chloride. Phosphonate derivatives Ia are prepared using genistein and a phosphonyl halide (e.g., phosphonyl chloride) in an inert solvent such as DCM with a base such as DMAP, Et3N or pyridine. Amino acid derivatives such as Ii, Ij and Ik can be prepared by monoacylation of genistein at the 4′ position with a single equivalent of an amino acid or an activated derivative, and the amine group is protected in a conventional manner and then deprotected. Derivatives at other positions are prepared by, for example, alkylation protection of the 4'-hydroxyl group of genistein, acylation of the protected genistein and deprotection.

[0079] Example

[0080] Except for Example 9, detailed information of the examples is described in Wei et al., "Cannabinoid receptor 1 antagonist genistein attenuates marijuana-induced vascular inflammation", Cell, 185(10), 1676-1693(2022), published online on April 29, 2022: https: / / doi.org / 10.1016 / j.cell.2022.04.005 and in the supplementary materials of the article, which is incorporated herein by reference.

[0081] Example 1: Biobank Screening for Associations between Cannabis Use and Adverse Cardiovascular Events

[0082] The UK Biobank is a large prospective cohort study that contains genetic and phenotypic data of 500,000 individuals aged 40-69 years recruited between 2006 and 2010 and followed up continuously over time (see Bycroft et al., "The UK biobank resource with deep phenotyping and genomic data", Nature, 562, 203-209 (2018)). The number of cannabis users and non-cannabis users in the UK Biobank (http: / / biobank.ctsu.ox.ac.uk / crystal / field.cgi?id=20453). Those who answered "no" to ever using cannabis were identified as non-cannabis users; while the remaining individuals were segregated according to the frequency of cannabis use, and those who answered "yes" to cannabis use more than once a month were identified as cannabis users. The number of cannabis users and non-cannabis users who reported a history of myocardial infarction was obtained; and the incidence of MI in cannabis and non-cannabis users was subsequently determined. To determine the incidence of MI in cannabis and non-cannabis users under 50 years of age, the same procedure was followed for cannabis and non-cannabis users under 50 years of age at the time of the survey. Of the 157,331 biobank participants who completed the cannabis use survey, 122,455 were identified as non-cannabis users, of whom 2776 had annotated MI and 548 had premature MI (MI under 50 years of age), with an incidence of 0.45%, while 11,914 were identified as cannabis users, of whom 217 had annotated MI and 63 had premature MI, with an incidence of 0.53%. Using a logistic regression model, cannabis use was a statistically significant positive predictor of MI, controlling for age, body mass index, and sex.

[0083] Inflammation is central to the pathogenesis of atherosclerosis, and Olink proteomics was used to analyze plasma from recreational marijuana users to detect inflammatory markers. Twenty recreational marijuana users who had not used marijuana within 24 hours were recruited and smoked only one marijuana cigarette. Blood was drawn continuously to evaluate the Δ 9 -THC levels (Lynch et al., “Correlation of breath and bloodΔ 9-tetrahydrocannabinol concentrations and release kinetics following controlled administration of smoked cannabis”, Clin. Chem., 65, 1171-1179 (2019)). After smoking cannabis, plasma samples were continuously drawn from 18 participants at 15-minute intervals over 180 minutes using sodium citrate tubes. Olink inflammation map analysis showed that at 90 minutes, several inflammatory cytokines were upregulated, including: TGFβ, CCL4, CCL19, CXCL6, CXCL10, CXCL11, IL8, MCP2, MCP4, TNF, and CCL1. These upregulated cytokines are all related to atherosclerosis. FLT3 was downregulated after smoking cannabis, which is also related to Flt3 (- / -) Ld (- / -) Accelerated atherosclerosis in mice.

[0084] Example 2: Genistein binds to CB1 receptor and inhibits CB1 activity

[0085] Genistein was identified as a potential CB1 antagonist by virtual screening of the SWEETLEAD chemical database against four known selective CB1 antagonists (rimonabant, otenabant, AM251, and DBPR-211) using the ROCS software suite, and molecular docking using the Schrodinger GLIDE docking function and the selective CB1 blocker AM6538 as a positive control. In vitro GTPase assays revealed that genistein acted as a neutral antagonist against CB1, and radioligand binding assays of predicted targets bound by genistein showed that genistein was a potential CB1 antagonist with an IC of 150 nm. 50 Binds to human CB1.

[0086] Example 3.Δ 9 -THC induces cytotoxicity in human endothelial cells

[0087] The Δ 9 - THC cytotoxicity: human endothelial cells (human umbilical vein endothelial cells (HUVEC) and human coronary artery endothelial cells (HCAECs)), human embryonic stem cell-derived cardiomyocytes (H7 hESC-CM) and human cardiac fibroblast-ventricular cells (NHCF-V). 9 -THC induces cytotoxicity in human endothelial cells without any adverse effects on cardiomyocytes or cardiac fibroblasts. Inflammation and oxidative stress can lead to endothelial dysfunction.9 -THC induces the expression of inflammation-related genes and reduces the expression of antioxidant-related genes. 9 -THC phenotype in female patients with environmental exposure, while human induced pluripotent stem cell-derived endothelial cells (hiPSC-ECs) were not exposed to the aforementioned environment and were generated from healthy individuals. hiPSC-ECs formed capillary-like tubes in vitro, mimicking angiogenesis, while Δ 9 -THC also induced cytotoxicity. The expression of cannabinoid receptors in hiPSC-ECs was examined using hiPSC-derived neurons and human erythroblasts (HEL92.1.7) as a positive control. CB1 receptors, but not CB2 receptors, were expressed in hiPSC-ECs, thus hiPSC-ECs can be used to mimic Δ 9 -THC affects the vascular system via CB1 receptors.

[0088] Δ 9 -THC also reduced the mRNA expression of antioxidant-related genes, including superoxide dismutase 1 (SOD1), superoxide dismutase 2 (SOD2), catalase (CAT), and glutathione peroxidase 1 (GPX1). 9 -THC treatment upregulated ROS-related genes involved in endothelial dysfunction in hiPSC-ECs, such as NADPH oxidase 1 (NOX1) and inducible nitric oxide synthase (iNOS). 9 -THC-treated hiPSC-ECs also induced cellular oxidative stress, with elevated levels of hydrogen peroxide (H2O2).

[0089] Example 4: Δ 9 -THC induces inflammation and NF-κB activation in hiPSC-ECs

[0090] Detected Δ 9 -THC-treated hiPSC-ECs. Proinflammatory cytokines and chemokines in response to Δ 9 -THC increased, while the specific inhibitor of NF-κB transcription factor IκB (IκB) was affected by Δ 9 -HC inhibits TNFα from promoting vascular dysfunction; and Δ 9 -After THC treatment, the concentration of TNFα in the culture medium of hiPSC-EC cells increased. The adhesion of monocytes to endothelial cells is associated with the development of atherosclerosis; Δ 9 -THC treatment showed that monocyte adhesion to hiPSC-ECs increased. The washout experiment was used to evaluate the 9- Longitudinal effects of THC-induced inflammation in hiPSC-ECs. 9 -After 48 hours of THC treatment, the supernatant in hiPSC-ECs was replaced with fresh medium. The expression of inflammation-related genes in hiPSC-ECs was evaluated every other day for two weeks. 9 -THC-induced expression of pro-inflammatory cytokines and chemokines persisted for 8-10 days after initial exposure. 9 -THC-induced inflammation lasts four to five times longer than the initial exposure.

[0091] Example 5: Genistein reverses Δ in hiPSC-EC by inhibiting CB1 9 -THC-induced oxidative stress and inflammation.

[0092] CB1 receptors involved in Δ 9 - Pathological effects of THC on the vascular system. Pharmacological and genetic inactivation of CB1 receptors can be used to determine whether CB1 receptors are expressed in hiPSC-ECs. 9 The selective CB1 antagonist AM6545 reversed the Δ 9 -THC-induced mRNA expression of inflammation and oxidative stress-related genes; and by knocking down CB1 by siRNA, Δ 9 -THC-induced effects were also reversed. CRISPR interference (CRISPRi) of CB1 expression reversed the Δ 9 -THC-induced inflammation and oxidative stress. Genistein is known to improve TNFα-mediated inflammation and oxidative stress in endothelial cells (Jia et al., "Genistein inhibits TNF-alpha-induced endothelialinflammation through the protein kinase pathway A and improves vascular inflammation in C57BL / 6 mice", Int. J. Cardiol., 168, 2637-2645 (2013)); therefore, genistein requires CB1 receptors to attenuate the inflammatory effects of TNFα.

[0093] In hiPSC-ECs, genistein improved 9 -THC inhibited the expression profile of antioxidant genes and also had a beneficial effect on iNOS and NOX1 expression. 9 -THC-treated hiPSC-ECs are more likely to remain quiescent and not participate in the pathogenesis of atherosclerosis. Genistein not only reversed the 9-THC-induced monocyte adhesion to hiPSC-ECs and also attenuated NF-κB phosphorylation.

[0094] Toll-like receptors (TLRs) are components of the innate immune system that recognize molecular patterns of microbial components, and the TLR4 / NF-κB signaling pathway can promote vascular inflammation in endothelial cells. 9 -THC-induced TLR4 expression, while genistein abolished its expression. And genistein reversed the Δ 9 -THC-induced mRNA expression of pro-inflammatory cytokines and chemokines. 9 -THC-induced inflammation recovery time was shortened from 8-10 days to 4-6 days. Genistein alleviated the Δ 9 -THC-induced oxidative stress and inflammation.

[0095] Example 6: Genistein reverses Δ in a mouse model 9 -THC-induced endothelial dysfunction, oxidative stress, and inflammation.

[0096] Male C57BL / 6J mice were injected intraperitoneally with the vector Δ 9 -THC or Δ 9 -THC+genistein treatment. Although oral ingestion or smoking is a more common route of ingestion in humans, LC-MS analysis showed that this mouse model produced ∼100 ng / mL of Δ 9 -THC plasma concentrations, which are comparable to the concentrations of smoking a marijuana cigarette. Male C57BL / 6J mice aged 7 weeks were obtained from Jackson Laboratory (Bar Harbor, ME, USA). 9 -THC or Δ 9-THC + genistein (n = 5 / group) treated mice for 30 days and then killed. Organs were collected, weighed, and fixed with 4% paraformaldehyde (PFA). The thoracic aorta (TA) of all groups was surgically removed and the surrounding connective tissue was cleared. The TA was transferred to ice-cold Krebs'-Henseleit solution and cut into 2 mm segments. The arterial segments were installed in a linear myograph (wire-myograph) chamber (DanishMyo Technology [DMT]) for isometric tension recording. The chamber was filled with Krebs'-Henseleit solution. All chambers were inflated with 95% O2 / 5% CO2 and the temperature was kept constant at 37°C to simulate physiological conditions. After manual stabilization and standardization procedures, the PowerLab4 / 25-Chart7 acquisition system (ADInstruments Ltd) was used to record the force and convert it into tension. The TA segment was precontracted with 1-3 mM 5HT serotonin (5HT) or U46619. Cumulative application of acetylcholine (1-10 mM) was performed and the induced vasodilation was measured. Subsequently, concentration-response curves were established for 3 mice per group. Time-matched application of dimethyl sulfoxide (DMSO) was performed in a separate chamber as a control for all experiments. Linear myograms showed that Δ 9 -THC induced endothelial dysfunction in mice, whereas genistein alleviated this effect.

[0097] Genistein and the known CB1 antagonist rimonabant improved Δ 9 -THC-induced mRNA expression of inflammation in mouse thoracic artery tissue; genistein also rescued the expression of oxidative stress-related genes. The expression of inflammation- and oxidative stress-related genes is associated with vasodilation. Genistein also attenuated NF-κB phosphorylation and SOD expression in mouse serum. Δ 9 Administration of -THC reduced circulating levels of the antioxidant glutathione, which was ameliorated by co-treatment with genistein. Analysis of C57BL / 6J plasma showed that interleukins IL-6, IL-3, and IL-10, which are associated with an increased risk of atherosclerosis, were elevated in Δ 9 -THC treatment, genistein co-treatment significantly reduced the expression of these inflammatory cytokines. Taken together, these results suggest that genistein is able to reverse Δ 9 -THC-induced effects. Although genistein had a protective effect on the vascular system, it did not show any toxicity based on body weight and H&E staining of various organs.

[0098] Example 7: Δ 9 - Effects of THC and genistein on atherosclerosis

[0099] In order to study Δ 9 -THC and genistein in the development of chronic atherosclerosis in LDL receptor knockout mice (B6.129S7-Ldlr tm1Her / J ) were fed a high-fat diet for 12 weeks and received the following treatments: vehicle control Δ 9 -THC, or Δ 9 -THCs+genistein (n=10-12 / group). All groups showed an increase in body weight, and Δ 9 - Successful administration of THC. Δ 9 -THC or Δ 9 Neither -THC+genistein combination treatment affected serum lipid profiles or blood pressure. After 12 weeks, mice were euthanized and the area of ​​atherosclerotic lesions was examined by cross-section of the aortic root and in-plane analysis of the thoracic aorta. 9 -THC-treated mice showed a significant increase in plaque size, whereas co-treatment with genistein improved plaque size. Macrophage recruitment to the aortic root was analyzed using anti-CD68 antibody staining of aortic plaques. 9 -THC administration significantly increased the CD68-positive area, and co-treatment with genistein rescued the CD68-positive area. These results suggest that Δ 9 -THC exacerbated atherogenesis and macrophage recruitment in atherosclerotic plaques, whereas genistein co-treatment ameliorated this.

[0100] We also used the ApoE- / - mouse model to study the 9 - Effects of THC and genistein combination therapy on atherosclerosis. - / - Mice underwent partial carotid artery ligation (PCAL). After PCAL, the mice were divided into three groups: vehicle control group; Δ 9 -THC;Δ 9 -THC+genistein (n=5 / group). All mice were fed a high-fat diet for 10 days. At the end of the treatment period, mice were euthanized and histologically analyzed. Oil red O staining of the ligated carotid artery showed increased fat deposition compared with the unligated contralateral vessel; and H&E staining showed thickening of the neointimal layer, fat deposition, and increased macrophage recruitment in the atherosclerotic plaques of the ligated carotid artery. Oil red O staining found that Δ 9 -THC treatment increased plaque area, while Δ 9-THC+genistein combination treatment improved plaque size. Macrophage recruitment was tested using macrophage-specific F4 / 80 and CD68 antibodies. 9 -THC administration significantly increased the F4 / 80 positive area, while combined treatment with genistein reduced the F4 / 80+ positive area. Immunohistochemical analysis with CD68-specific antibodies showed that Δ 9 -THC administration significantly increased the CD68-positive area, whereas co-treatment with genistein reduced the CD68-positive area. - / - The results of the model are consistent with that of ApoE - / - The PCAL mouse model found that Δ 9 -THC increased plaque size and reduced macrophage recruitment, whereas genistein co-treatment improved these markers of atherosclerosis in ligated carotid arteries.

[0101] Example 8: Genistein is primarily peripherally restricted, binds to CB1 receptors, and does not attenuate Δ 9 -THC neurobehavioral effects

[0102] Although genistein alleviated Δ 9 -THC-induced vascular dysfunction, but direct evidence of genistein binding to CB1 was explored using fluorescently labeled genistein (BODIPY517 / 547-genistein). In the CB1 radioligand binding assay, the IC 50 It is 357nM, and almost all hiPSC-EC cells are labeled after 12 hours of culture. In vivo binding is studied using intravenous injection of BODIPY517 / 547-genistein in C57BL / 6J mice. After 48 hours, BODIPY517 / 547-genistein was detected in abdominal viscera, thoracic aorta, heart and lungs, but the lowest was detected in the brain. This is consistent with previous reports (Yang et al., "Bioavailability and pharmacokinetics of genistein:mechanistic studies on itsADME", Anticancer Agents Med.Chem., 12, 1264-1280 (2012)), indicating that the blood-brain barrier (BBB) ​​permeability of genistein is poor.

[0103] Neurobehavioral test (Billy Martin tetrad): Although BODIPY517 / 547 has excellent bioavailability, genistein has poor blood-brain barrier permeability and is therefore worth exploring.9 - Neurological effects of THC in combination with genistein. 9 -THC's neurobehavioral effects include decreased activity, analgesia, hypothermia, and sedation, which is known as the Billy Martin quadruple (see Wiley et al., "Cannabinoid pharmacological properties common to other centrally acting drugs", Eur. J. Pharmacol., 471, 185-193 (2003)). Δ 9 -THC's sedative and analgesic effects may have therapeutic benefits; and, while protecting blood vessels from harmful effects, genistein may antagonize Δ 9 -THC's neurobehavioral quadruple effect. 9 -THC or combined treatment was tested in C57BL / 6J mice 9 -Neurotoxic effects of THC + genistein co-administration. This quadruple effect was evaluated using an activity chamber for mobility, a hot plate for analgesia, a rectal probe for hypothermia, and a rod test for sedation. Male C57Bl / 6J mice aged 6-7 weeks from the Jackson Laboratory were used in the study. All behavioral tests were performed during the dark cycle of the animals. Mice were randomly divided into different dose groups according to their body weight. Δ 9 -THC (20 mg / kg ip in a vehicle of 5% ethanol, 5% Cremophor EL, and 90% isotonic saline) and genistein (50 mg / kg po in a corn oil vehicle) were divided into the following groups: Group 1: n=8, vehicle ip+vehicle po; Group 2: n=9, THC ip+vehicle op; Group 3: n=8, vehicle ip+genistein po; Group 4: n=9, THC i.p.+genistein op). In C57BL / 6J mice, Δ 9-THC caused decreased activity (outdoor activity chamber; tested before and 60 min after dosing), analgesia (hot plate apparatus set at 55°C; maximum test duration 30 s; latency to licking, flicking or jumping of the hind paw was recorded), hypothermia (rectal body temperature; tested before and 60 min after dosing), and sedation (rod test; a small metal rod (0.7 cm diameter, 10 cm length) was suspended 3-5 cm above a table and the mouse's forepaws were placed on the rod. The total duration that the mouse remained on the rod with one or both paws in a spastic state was recorded for a total of 60 s. If the mouse jumped over the rod, it was placed back to its original position on the rod up to 4 times. If the mouse jumped over the rod for the fifth time, a score of 0 s was assigned; tested before and 60 min after dosing). Genistein alone did not affect the tetrad effect, and genistein did not attenuate the Δ 9 - Neurobehavioral effects of THC in combination therapy.

[0104] Example 9: Human studies using genistein and genistein derivatives

[0105] Human subjects who ingest medicinal cannabinoids such as dronabinol and nabilone were randomized to placebo treatment or genistein treatment at 1 or 5 mg / kg / day. It was found that subjects treated with genistein showed a dose-related lower incidence of cardiovascular adverse effects of cannabinoid ingestion. Similar studies on genistein derivatives have also yielded similar results.

[0106] Although the invention has been described in conjunction with specific embodiments and examples, it will be apparent to one of ordinary skill in the art, in view of this technology and this disclosure, that equivalents to the specifically disclosed materials and methods will also be suitable for use in the present invention; and such equivalents are intended to be encompassed by the following claims.

Claims

1. Genistein or a genistein derivative for use in treating an adverse cardiovascular effect of a cannabinoid in a subject.

2. The genistein or genistein derivative according to claim 1, wherein The genistein or genistein derivative is a genistein derivative.

3. The genistein or genistein derivative according to claim 1 or 2, wherein The genistein or its derivative is a compound of formula I: or a pharmaceutically acceptable salt thereof, Where R 1 , R 2 and R 3 Each independently selected from H, (HO)2P(O)-, HOS(O)2-, H2NS(O)2-, H(OCH2CH2) 1-10 -, (CH3)2NCH2CH2-, morpholinyl, (C 1-6 alkyl)C(O)-[wherein C 1-6 The alkyl group may be optionally substituted by 1 or 2 groups selected from halogen, hydroxyl, C 1-4 Alkoxy, amino, C 1-4 A substituent consisting of the group consisting of an alkylamino group, a cyano group and an acetoxy group] and a substituent consisting of an acyl group of an amino acid or a hydroxy acid.

4. The genistein or genistein derivative according to claim 3, wherein The C 1-6 The alkyl group is selected from the group consisting of methyl, ethyl, isopropyl, isobutyl; and (acetoxy)methyl, (1-acetoxy)ethyl or (2-acetoxy)ethyl.

5. The genistein or genistein derivative according to claim 3, wherein The amino acid is alanine, aspartic acid, cysteine, glutamic acid, glycine, valine, isoleucine, leucine, methionine, phenylalanine, proline, serine, threonine, tyrosine or tryptophan.

6. The genistein or genistein derivative according to claim 3, wherein The hydroxy acid is an omega-hydroxy acid.

7. The genistein or genistein derivative according to claim 6, wherein The hydroxy acid is delta-hydroxyvaleric acid.

8. The genistein or genistein derivative according to claim 3, wherein The genistein derivatives are compounds of formula Ia-Il: or a pharmaceutically acceptable salt thereof.

9. The genistein or genistein derivative according to any one of claims 1 to 8, wherein The genistein or genistein derivative is formulated as a nanoparticle suspension.

10. The genistein or genistein derivative according to claim 9, wherein The genistein or genistein derivative consists of particles having a median particle size of less than about 200 nm, less than 150 nm, less than 100 nm, less than about 90 nm, less than about 80 nm, less than about 70 nm, or less than about 60 nm.

11. The genistein or genistein derivative according to any one of claims 1 to 10, wherein The genistein or genistein derivative is formulated with a water-soluble polymer.

12. The genistein or genistein derivative according to any one of claims 1 to 11, wherein The dosage of the genistein or genistein derivative is 1-5 mg / Kg / day.

13. The genistein or genistein derivative according to any one of claims 1 to 12, wherein The cannabinoids are selected from the group consisting of Δ 9 - The group consisting of tetrahydrocannabinol, nabilone or cannabidiol or mixtures thereof.

14. The genistein or genistein derivative according to any one of claims 1 to 13, wherein The adverse cardiovascular effects include one or more of the following: upregulation of proinflammatory cytokines and chemokines, adhesion of monocytes to cardiovascular endothelial cells, expression of genes related to oxidative stress such as NF-kB phosphorylation and SOD expression in endothelial cells.

15. The genistein or genistein derivative according to any one of claims 1 to 13, wherein The adverse cardiovascular effect is selected from the group consisting of myocardial infarction (MI), angina pectoris, arrhythmia, endothelial dysfunction, atherosclerosis, cardiomyopathy and metabolic dysfunction.